{
  "id": 10293219,
  "title": "Mirum to present phase 3 hepatitis delta study results Monday",
  "url": "https://urgent.news/2026/09/27/mirum-to-present-phase-3-hepatitis-delta-study-results-monday",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-27T21:04:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/mirum-to-present-phase-3-hepatitis-delta-study-results-monday-93CH-4919138"
  },
  "original_language": "en",
  "account": "Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is set to unveil the results of its Phase 3 AZURE-1 study on brelovitug for chronic hepatitis delta virus on Monday morning. The company will also share data from the Phase 2b stage of the study. Brelovitug, a fully human monoclonal antibody, is in late-stage development for treating chronic hepatitis delta virus. To participate in the conference call, U.S. callers should dial +1 833 461 5787, while international participants can use +1 585 542 9983, using access code 979912911. A webcast of the call will be available on Mirum's Investors section, with archived replay access post-call. Mirum Pharmaceuticals specializes in rare liver and genetic diseases, with its product portfolio including LIVMARLI, ATEBRIOZ, CHOLBAM, and CTEXLI. The company's pipeline also includes volixibat and MRM-3379, which are in late-stage development for primary sclerosing cholangitis, primary biliary cholangitis, and Fragile X syndrome, respectively.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}